eMedicine Specialties > Urology > Stones

Hypocitraturia

Author: George Bennett Stackhouse IV, MD, Assistant Professor of Surgery, Uniformed Services University of Health Sciences, Bethesda, MD; Director, Endourology, Walter Reed Army Medical Center, Washington, DC
Coauthor(s): Howard H Woo, MD, Consulting Staff, Clinical Instructor, Department of Urology, Ochsner Urology Institute
Contributor Information and Disclosures

Updated: Jan 27, 2010

Introduction

Background

Hypocitraturia, a low amount of citrate in the urine, is an important risk factor for kidney stone formation. Citrate in the urine has long been recognized as an inhibitor of calcium salt crystallization. Citrate is the dissociated anion of citric acid, a weak acid that is both ingested in the diet and produced endogenously in the tricarboxylic acid cycle. The mean urinary citrate excretion is 640 mg/d in healthy individuals. Hypocitraturia usually is defined as citrate excretion of less than 320 mg/d, but this definition has been challenged as inadequate for recurrent stone formers. Severe hypocitraturia is citrate excretion of less than 100 mg/d, and mild-to-moderate hypocitraturia is citrate excretion of 100-320 mg/d. Other definitions include a urine citrate level of less than 220 mg/d for both men and women, regardless of age, or less than 115 mg/d in men and less than 200 mg/d in women.

These definitions have been called into question by several kidney stone experts and researchers. They feel that these reference range values were selected somewhat arbitrarily from statistical models and large populations of healthy subjects and do not necessarily indicate the optimal level for a calcium stone former. While hypocitraturia currently is defined as the excretion of less than 320 mg of citrate per day, most healthy people actually will have daily urinary citrate excretions of over 600 mg.

Researchers believe that the current definition ignores urinary citrate concentration, which may be far more important than the gross total 24-hour urinary citrate excretion. Further, they argue that optimal urinary citrate levels for calcium stone formers are likely to be closer to the statistical average or median of the reference group than to the lower limits of the healthy range. Using this logic, optimal daily urinary citrate levels for calcium stone formers would probably range from 500-800 mg, and one group uses 450 mg/d in men and 550 mg/d in women as cutoff values in stone formers.

Pathophysiology

The excretion of citrate in the urine is a function of filtration, reabsorption, peritubular transport, and synthesis by the renal tubular cell. The proximal tubule reabsorbs most (70-90%) of the filtered citrate, and citrate secretion is negligible. Acid-base status plays the most significant role in citrate excretion. Alkalosis enhances citrate excretion, while acidosis decreases it. In acidosis, increased citrate utilization by the mitochondria in the tricarboxylic acid cycle occurs. This results in lower intracellular levels of citrate, facilitating citrate reabsorption and hence reducing citrate excretion. Citrate excretion is impaired by acidosis, hypokalemia (causing intracellular acidosis), high–animal protein diet (with an elevated acid-ash content), and urinary tract infection (UTI).

Citrate plays several important roles in the mechanism of urinary stone formation. First, citrate complexes to calcium ions in the urine, reducing calcium ion activity, which results in lowering the urinary supersaturation of calcium phosphate and calcium oxalate. This complexing action is not completely understood and has been recently shown to involve the formation of a calcium-citrate-phosphate species. This process is pH-dependent, and increases in urinary pH levels appear to be more important in the formation of this complex than increases in available citrate per se. Second, citrate has a direct inhibitory effect on the crystallization and precipitation of calcium salts.

Citrate also increases the calcium oxalate aggregation inhibitory activity of urine macromolecules (eg, Tamm-Horsfall protein) and may reduce the expression of urinary osteopontin, which is an important component of the protein matrix of urinary stones. In addition, urinary citrate excretion can increase urinary pH, which is a factor in uric acid crystallization and uric acid stone formation, as well as in the calcium-citrate-phosphate complex formation described above.

In summary, hypocitraturia (low urine citrate excretion) enhances urine calcium salt supersaturation and reduces calcium crystallization inhibition, increasing the risk of calcium nephrolithiasis. It also may play a role in uric acid solubility and uric acid stone formation.

Frequency

United States

Hypocitraturia has been reported in 15-63% of all patients with nephrolithiasis, but it is probably a significant factor in about a third of all kidney stone patients. This condition may exist as a single abnormality (10%) or in conjunction with other metabolic disorders of calcium nephrolithiasis (50%).

International

The incidence of nephrolithiasis varies among populations; Ramello et al reported rates of 1-5% in Asia, 5-9% in Europe, 13% in North America, and 20% in Saudi Arabia.1 The incidence of hypocitraturia among these populations is not reported.

Mortality/Morbidity

Hypocitraturia commonly is observed in patients with nephrolithiasis, metabolic acidosis, and chronic diarrheal syndromes. Hypocitraturia itself may not be associated with significant mortality or morbidity; however, potential complications of nephrolithiasis secondary to hypocitraturia can be significant. Potential morbidity due to nephrolithiasis includes hematuria, ureteral obstruction, UTI, urosepsis, and loss of kidney function.

Race

In general, epidemiologic studies have shown that blacks in the United States experience less stone disease than whites by a ratio of approximately 1:4. A review of 1,141 stone formers showed similar rates of hypocitraturia among whites, blacks, and Asians.

Sex

Calcium-containing stones occur 3 times more often in men than in women. The 24-hour measurement of urinary citrate in non–stone-forming subjects is higher in women (mean value of 710 mg) than in men (mean value of 531 mg). However, hypocitraturia is more common in stone-forming women than in men.

Age

The incidence of stone diseases is highest in persons aged 30-50 years. Hypocitraturia is more common in premenopausal women with stone disease than in postmenopausal stone-forming women. Geriatric stone patients have a higher incidence of isolated hypocitraturia (29%) than younger stone formers (17%).

Clinical

History

Hypocitraturia is diagnosed based on a metabolic evaluation of a 24-hour urine collection in patients with nephrolithiasis. The stone chemical composition and elements of the clinical history may help to determine the cause of stone formation and identify potential patients with hypocitraturia. The important elements in the history are outlined below.

  • Medical history
    • Personal history of nephrolithiasis: Previous stone passage, interventional procedures, and previous stone composition are important in history taking. A history of multiple stone passages and rapid recurrent stone formation may indicate a fundamental metabolic cause, such as primary hyperparathyroidism or renal tubular acidosis. The necessity for multiple interventional procedures, whether endoscopic or open surgical, implies the growth of larger stones. This may be indicative of a more malignant form of stone disease, such as infected lithiasis.
    • Chronic diarrhea, inflammatory bowel disease, ileostomy, and colostomy (fluid loss due to diarrhea)
    • Recurrent UTI: As many as 30% of patients with calcium oxalate stones have a history of an infection with Escherichia coli.
    • Systemic disease (eg, renal tubular acidosis [RTA])
    • Horseshoe kidney: Stones in patients with horseshoe kidney have previously been attributed solely to urinary stasis, but a more recent review shows that most have predisposing metabolic stone risk factors, and more than 50% of patients with horseshoe kidney and stones have hypocitraturia.
  • Surgical history
    • Past history of shock wave lithotripsy, ureteroscopy, percutaneous nephrolithotomy, or open stone surgery
    • Patients who have undergone enterocystoplasty (augmentation cystoplasty) or who have an intestinal urinary reservoir (neobladder, continent urinary diversion) are usually prone to infection stones but have also been found to have hypocitraturia associated with uninfected stone formation.
    • Obesity is related to increased risk for calcium oxalate stone formation, but not specifically to hypocitraturia. However, many surgical treatments for obesity, including jejunoileal bypass and roux-en-Y procedures, lead to hyperoxaluria and hypocitraturia, resulting in urinary stone disease.
  • Diet and fluid intake
    • High meat intake increases the urinary excretion of calcium, oxalate, and uric acid and decreases urinary pH and citric excretion. The recent popularity of high-protein, low-carbohydrate diets for weight loss has led to concern about increased risk of stone formation, as these diets have been shown to be associated with decreased urinary citrate and pH levels and increased urine calcium and sodium levels in both the induction and maintenance phases.
    • An excessive amount of sodium can result in hypocitraturia.
  • Stone-provoking medications
    • High sodium intake
    • Hypercalciuria can result from administration of corticosteroids, aluminum-containing antacids, loop diuretics, and vitamin D.
    • Hypocitraturia is often associated with thiazide diuretic or acetazolamide administration. More recently, topiramate has been found to be associated with an increased risk for urinary stones2 and to cause hypocitraturia by its inhibition of renal carbonic anhydrases.3
  • Social history
    • Strenuous exercise
    • High sodium intake

Physical

No specific physical findings are related to hypocitraturia. However, patients with nephrolithiasis often experience acute and extremely painful episodes of renal colic, with associated costovertebral angle tenderness. Abdominal tenderness may develop during renal colic, but peritoneal signs are not found. Renal colic due to kidney stone disease prompts one of the most common reasons for visits to the emergency department for urological care.

Causes

The following are causes of hypocitraturic calcium nephrolithiasis: distal RTA, chronic diarrheal syndrome, thiazide diuretic or acetazolamide administration, diet high in animal protein, strenuous physical exercise, high sodium intake, gout or gouty diathesis, and active UTI.

  • Renal tubular acidosis: RTA is a term applied to several clinical syndromes of metabolic acidosis that result from specific defects in renal tubular hydrogen ion secretion and urinary acidification. One of the more common presentations of hypocitraturia is distal RTA, which can occur in a complete or incomplete form. The complete form is characterized by hyperchloremic metabolic acidosis, hypokalemia, and elevated urine pH, while the incomplete form exhibits normal serum electrolytes but the inability to acidify urine following an ammonium chloride load. Both forms can be associated with hypercalciuria and profound hypocitraturia. Combined with alkaline urine, such abnormalities place patients at high risk for calcium phosphate or, less commonly, calcium oxalate stone formation.
  • Chronic diarrheal syndrome: Chronic diarrheal syndrome results in fluid loss and intestinal alkali loss. Patients with chronic diarrhea and inflammatory bowel disease frequently have hypocitraturia due to bicarbonate loss from the intestinal tract. Hypocitraturia caused by RTA or chronic diarrheal syndrome is associated with other metabolic abnormalities (eg, hypercalciuria, hyperuricosuria) or may occur alone. In chronic diarrheal syndrome, other risk factors for stone formation often are present (eg, low urinary volume, hyperoxaluria, hypomagnesuria, low urinary pH).
  • Thiazide diuretic or acetazolamide administration: Thiazide therapy may induce hypocitraturia owing to hypokalemia with resultant intracellular acidosis. Acetazolamide (a carbonic anhydrase inhibitor used in the treatment of glaucoma) produces changes in urine composition that are similar to those found in distal RTA. It results in hyperchloremic acidosis due to its action of inhibiting sodium bicarbonate reabsorption in the proximal tubule. Thus, hypocitraturia often occurs due to metabolic acidosis.
  • Diet high in animal protein: A diet rich in animal protein (from elevated acid-ash content) may produce hypocitraturia. Animal proteins contain sulfate and phosphate moieties that are excreted as acids.
  • Strenuous physical exercise (that causes lactic acidosis) and increased sodium intake can likewise produce hypocitraturia.
  • UTI with bacteria that degrade citrate lowers urinary citrate levels.
  • Gout and gouty diathesis are conditions that involve excessive serum uric acid, which often is associated with nephrolithiasis. Controlling the uric acid problem and its potential contribution to stone formation may involve limiting purine intake, controlling hepatic uric acid production, monitoring urinary uric acid levels, and checking or altering urinary acidity.

More on Hypocitraturia

Overview: Hypocitraturia
Differential Diagnoses & Workup: Hypocitraturia
Treatment & Medication: Hypocitraturia
Follow-up: Hypocitraturia
References

References

  1. Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J Nephrol. Nov-Dec 2000;13 Suppl 3:S45-50. [Medline].

  2. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. Sep 2007;6(5):547-57. [Medline].

  3. Warner BW, LaGrange CA, Tucker T, Bensalem-Owen M, Pais VM Jr. Induction of progressive profound hypocitraturia with increasing doses of topiramate. Urology. Jul 2008;72(1):29-32; discussion 32-3. [Medline].

  4. Wabner CL, Pak CY. Effect of orange juice consumption on urinary stone risk factors. J Urol. Jun 1993;149(6):1405-8. [Medline].

  5. Seltzer MA, Low RK, McDonald M. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol. Sep 1996;156(3):907-9. [Medline].

  6. Kessler T, Hesse A. Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects. Br J Nutr. Dec 2000;84(6):865-71. [Medline].

  7. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. Dec 1993;150(6):1761-4. [Medline].

  8. Pak CY, Fuller C, Sakhaee K. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. Jul 1985;134(1):11-9. [Medline].

  9. Annuk M, Backman U, Holmgren K. Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol. May 1998;32(3):177-80. [Medline].

  10. Breslau NA, Brinkley L, Hill KD. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab. Jan 1988;66(1):140-6. [Medline].

  11. Conway NS, Maitland AI, Rennie JB. The urinary citrate excretion in patients with renal calculi. Br J Urol. Mar 1949;21(1):30-8; Disc. 39-46. [Medline].

  12. Edin-Liljegren A, Grenabo L, Hedelin H. Concrement formation and urease-induced crystallization in urine from patients with continent ileal reservoirs. Br J Urol. Jul 1996;78(1):57-63. [Medline].

  13. Evans BM, MacIntyre I, Macpherson CR, Milne MD. Alkalosis in sodium and potassium depletion; with especial reference to organic acid excretion. Clin Sci (Lond). Feb 1957;16(1):53-65. [Medline].

  14. Gentle DL, Stoller ML, Bruce JE. Geriatric urolithiasis. J Urol. Dec 1997;158(6):2221-4. [Medline].

  15. Hamm LL. Renal handling of citrate. Kidney Int. Oct 1990;38(4):728-35. [Medline].

  16. Hess B, Zipperle L, Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol. Dec 1993;265(6 Pt 2):F784-91. [Medline].

  17. Leslie S. Potassium citrate and potassium citrate therapy. In: Savitz G, Leslie S, eds. The Kidney Stones Handbook: A Patient's Guide to Hope, Cure, and Prevention. 2nd ed. Roseville, Calif: Four Geez Press; 1999:90-2.

  18. Maloney ME, Springhart WP, Ekeruo WO, Young MD, Enemchukwu CU, Preminger GM. Ethnic background has minimal impact on the etiology of nephrolithiasis. J Urol. Jun 2005;173(6):2001-4. [Medline].

  19. Mattle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate--a critical review. Urol Res. May 2005;33(2):73-9. [Medline].

  20. Menon M, Mahle CJ. Prevalence of hyperoxaluria in idiopathic calcium oxalate urolithiasis: relationship to other metabolic abnormalities (Abstract 458). Presented at American Urological Association. Las Vegas;1983.

  21. Menon M, Mahle CJ. Urinary citrate excretion in patients with renal calculi. J Urol. Jun 1983;129(6):1158-60. [Medline].

  22. Menon M, Parulkar BG, Drach GW. Urinary lithiasis: etiology, diagnosis, and medical management. In: Campbell's Urology. 7th ed. Philadelphia, Pa: WB Saunders; 1998:2661-733.

  23. Mosby-Year Book. Mosby-Year Book. Mosby's GenRx: The Complete Reference for Generic and Brand Drugs. 9th ed. Mosby-Year Book, Inc; 1999:1807.

  24. Nicar MJ, Peterson R, Pak CY. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol. Mar 1984;131(3):430-3. [Medline].

  25. Nicar MJ, Skurla C, Sakhaee K. Low urinary citrate excretion in nephrolithiasis. Urology. Jan 1983;21(1):8-14. [Medline].

  26. Pak CY. Citrate and renal calculi. Miner Electrolyte Metab. 1987;13(4):257-66. [Medline].

  27. Pak CY. Hypercalciuric calcium nephrolithiasis. In: Resnick MI, Pak CYC, eds. Urolithiasis: A Medical and Surgical Reference. Philadelphia, Pa: WB Saunders; 1990:79-88.

  28. Pak CY, Skurla C, Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol. Nov 1985;134(5):867-70. [Medline].

  29. Preminger GM, Pak CY. Eventual attenuation of hypocalciuric response to hydrochlorothiazide in absorptive hypercalciuria. J Urol. Jun 1987;137(6):1104-9. [Medline].

  30. Preminger GM, Sakhaee K, Skurla C. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. Jul 1985;134(1):20-3. [Medline].

  31. Raj GV, Auge BK, Assimos D, Preminger GM. Metabolic abnormalities associated with renal calculi in patients with horseshoe kidneys. J Endourol. Mar 2004;18(2):157-61. [Medline].

  32. Reddy ST, Wang CY, Sakhaee K. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis. Aug 2002;40(2):265-74. [Medline].

  33. Robertson WG, Woodhouse CR. Metabolic factors in the causation of urinary tract stones in patients with enterocystoplasties. Urol Res. Aug 2006;34(4):231-8. [Medline].

  34. Rodgers A, Allie-Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant. Feb 2006;21(2):361-9. [Medline].

  35. Rudman D, Dedonis JL, Fountain MT. Hypocitraturia in patients with gastrointestinal malabsorption. N Engl J Med. Sep 18 1980;303(12):657-61. [Medline].

  36. Ruml LA, Pearle MS, Pak CY. Medical therapy, calcium oxalate urolithiasis. Urol Clin North Am. Feb 1997;24(1):117-33. [Medline].

  37. Sakhaee K, Alpern R, Jacobson HR. Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab. Feb 1991;72(2):396-400. [Medline].

  38. Sakhaee K, Harvey JA, Padalino PK. The potential role of salt abuse on the risk for kidney stone formation. J Urol. Aug 1993;150(2 Pt 1):310-2. [Medline].

  39. Sakhaee K, Poindexter JR, Griffith CS, Pak CY. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J Urol. Sep 2004;172(3):958-61. [Medline].

  40. Sakhaee K, Williams RH, Oh MS. Alkali absorption and citrate excretion in calcium nephrolithiasis. J Bone Miner Res. Jul 1993;8(7):789-94. [Medline].

  41. Scott WW, Huggins C, Selman BC. Metabolism of citric acid in urolithiasis. J Urol. 1943;50:202.

  42. Siener R, Glatz S, Nicolay C. The role of overweight and obesity in calcium oxalate stone formation. Obes Res. Jan 2004;12(1):106-13.

  43. Yasui T, Sato M, Fujita K. Effects of citrate on renal stone formation and osteopontin expression in a rat urolithiasis model. Urol Res. Feb 2001;29(1):50-6. [Medline].

Further Reading

Keywords

citrate, citric acid, nephrolithiasis, calcium nephrolithiasis, calcium oxalate, calcium phosphate, alkalinization, uric acid, potassium citrate

Contributor Information and Disclosures

Author

George Bennett Stackhouse IV, MD, Assistant Professor of Surgery, Uniformed Services University of Health Sciences, Bethesda, MD; Director, Endourology, Walter Reed Army Medical Center, Washington, DC
George Bennett Stackhouse IV, MD is a member of the following medical societies: Alpha Omega Alpha, American Urological Association, Phi Beta Kappa, Society of Government Service Urologists, and Society of Laparoendoscopic Surgeons
Disclosure: emedicine Honoraria Other

Coauthor(s)

Howard H Woo, MD, Consulting Staff, Clinical Instructor, Department of Urology, Ochsner Urology Institute
Howard H Woo, MD is a member of the following medical societies: American Urological Association
Disclosure: Pfizer Honoraria Speaking and teaching; GlaxoSmith Klein Honoraria Speaking and teaching; Astella Honoraria Speaking and teaching; Novatis Honoraria Speaking and teaching

Medical Editor

Leonard Gabriel Gomella, MD, FACS, The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Thomas Jefferson University
Leonard Gabriel Gomella, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Urological Association, Sigma Xi, Society for Basic Urologic Research, Society of University Urologists, and Society of Urologic Oncology
Disclosure: GSK Consulting fee Consulting; Astra Zeneca Honoraria Speaking and teaching; Watson Pharmaceuticals Consulting fee Consulting

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Gyrus-ACMI Honoraria Speaking and teaching

Chief Editor

Bradley Fields Schwartz, DO, FACS, Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.